We provide all available chemotherapy options, including continuous infusion chemotherapy, which is given slowly over one or more days through a pump that you carry with you. (mottchildren.org)
The KEYNOTE - 45 study randomised 542 patients from 29 countries between November 2014 and November 2015 to either pembrolizumab (200 mg, given intravenously once every three weeks for up to 24 months) or one of three chemotherapy options chosen by study investigators. (sciencedaily.com)
«Our focus was to identify drugs that we could move quickly from the laboratory to the clinic where new chemotherapy options are desperately needed for these high - risk medulloblastoma patients,» said the study's corresponding author Martine Roussel, Ph.D., a member of the St. Jude Department of Tumor Cell Biology. (sciencedaily.com)